- Home
- FHN vs BMRN Comparison
FHN vs BMRN Comparison
Compare FHN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHN | BMRN |
|---|---|---|
| Founded | 1864 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | FHN | BMRN |
|---|---|---|
| Price | $22.86 | $53.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 19 |
| Target Price | $24.05 | ★ $88.42 |
| AVG Volume (30 Days) | ★ 5.7M | 3.0M |
| Earning Date | 01-15-2026 | 10-27-2025 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | 20.88 | ★ 59.53 |
| EPS | 1.65 | ★ 2.68 |
| Revenue | ★ $3,184,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | $12.70 | $13.39 |
| Revenue Next Year | $2.54 | $7.57 |
| P/E Ratio | ★ $13.75 | $19.92 |
| Revenue Growth | 3.68 | ★ 12.39 |
| 52 Week Low | $15.19 | $50.76 |
| 52 Week High | $23.70 | $73.51 |
Technical Indicators
Market Signals| Indicator | FHN | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 46.19 |
| Support Level | $22.26 | $53.03 |
| Resistance Level | $22.98 | $54.66 |
| Average True Range (ATR) | 0.50 | 1.45 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 91.86 | 31.61 |
Price Performance
Historical ComparisonAbout FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.